| Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in acquisition, development, and commercialization of therapeutics in the fields of neurology and psychiatry in the United States and the European Union. It focuses on developing AXO-Lenti-PD, an in vivo lentiviral gene therapy investigational product candidate for the one-time treatment of Parkinson's disease. The company is also developing nelotanserin, a selective 5-HT2A receptor inverse agonist, which is in Phase II clinical trial for the treatment of visual hallucinations in patients with Lewy body dementia (LBD) and REM sleep behavior disorder in patients with LBD. In addition, it focuses on developing RVT-104, a combination of rivastigmine and a peripheral muscarinic receptor antagonist as treatments for patients with Alzheimer's disease or DLB. The company was formerly known as Roivant Neurosciences Ltd. and changed its name to Axovant Sciences Ltd. in March 2015. The company was founded in 2014 and is based in London, the United Kingdom. Axovant Sciences Ltd. is a subsidiary of Roivant Sciences Ltd. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Dexxon Holdings Ltd. | 10% Owner | Dec 18 | Buy | 1.00 | 10,000,000 | 10,000,000 | 99,285,714 | Dec 20 07:29 AM | | SVF Investments (UK) Ltd | 10% Owner | Dec 18 | Buy | 1.00 | 10,000,000 | 10,000,000 | 99,285,714 | Dec 20 07:06 AM | | QVT Associates GP LLC | 10% Owner | Dec 18 | Buy | 1.00 | 10,000,000 | 10,000,000 | 99,285,714 | Dec 20 06:15 AM | | Roivant Sciences Ltd. | 10% Owner | Dec 18 | Buy | 1.00 | 10,000,000 | 10,000,000 | 99,285,714 | Dec 20 06:02 AM | | Machado Patrick | 10% Owner | Dec 18 | Buy | 1.00 | 10,000,000 | 10,000,000 | 99,285,714 | Dec 20 06:03 AM | | VIKING GLOBAL INVESTORS LP | 10% Owner | Dec 18 | Buy | 1.00 | 10,000,000 | 10,000,000 | 99,285,714 | Dec 20 09:37 AM | | VIKING GLOBAL PERFORMANCE LLC | 10% Owner | Dec 18 | Buy | 1.00 | 10,000,000 | 10,000,000 | 99,285,714 | Dec 20 09:38 AM | | Lo Andrew | 10% Owner | Dec 18 | Buy | 1.00 | 10,000,000 | 10,000,000 | 99,285,714 | Dec 20 08:57 AM | | Bickerstaff George | Director | Aug 09 | Buy | 2.07 | 25,000 | 51,750 | 50,000 | Aug 13 05:26 PM | | SVF Investments (UK) Ltd | 10% Owner | Jun 05 | Buy | 1.75 | 14,285,714 | 25,000,000 | 89,285,714 | Jun 07 08:24 AM | | VIKING GLOBAL INVESTORS LP | 10% Owner | Jun 05 | Buy | 1.75 | 14,285,714 | 25,000,000 | 89,285,714 | Jun 07 08:20 AM | | VIKING GLOBAL PERFORMANCE LLC | 10% Owner | Jun 05 | Buy | 1.75 | 14,285,714 | 25,000,000 | 89,285,714 | Jun 07 08:21 AM | | Lo Andrew | 10% Owner | Jun 05 | Buy | 1.75 | 14,285,714 | 25,000,000 | 89,285,714 | Jun 07 08:46 AM | | Dexxon Holdings Ltd. | 10% Owner | Jun 05 | Buy | 1.75 | 14,285,714 | 25,000,000 | 89,285,714 | Jun 07 08:43 AM | | QVT Associates GP LLC | 10% Owner | Jun 05 | Buy | 1.75 | 14,285,714 | 25,000,000 | 89,285,714 | Jun 07 08:38 AM | | Machado Patrick | 10% Owner | Jun 05 | Buy | 1.75 | 14,285,714 | 25,000,000 | 89,285,714 | Jun 07 07:32 AM | | Roivant Sciences Ltd. | 10% Owner | Jun 05 | Buy | 1.75 | 14,285,714 | 25,000,000 | 89,285,714 | Jun 07 07:31 AM |
|
